These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 18347159)

  • 1. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.
    Logothetis CJ; Navone NM; Lin SH
    Clin Cancer Res; 2008 Mar; 14(6):1599-602. PubMed ID: 18347159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
    Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
    J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone metastases in prostate cancer: a targeted approach.
    Storey JA; Torti FM
    Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone directed therapies for prostate cancer.
    Bradley DA; Hussain M; Dipaola RS; Kantoff P
    J Urol; 2007 Sep; 178(3 Pt 2):S42-8. PubMed ID: 17644119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
    Carducci MA; Jimeno A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of targeted therapy in the treatment of advanced prostate cancer.
    Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M
    BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications.
    Chung LW
    Cancer; 2003 Feb; 97(3 Suppl):772-8. PubMed ID: 12548574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ; Hernandez-McClain J; Henary H
    Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions.
    Loberg RD; Gayed BA; Olson KB; Pienta KJ
    J Cell Biochem; 2005 Oct; 96(3):439-46. PubMed ID: 15988761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo models of prostate cancer metastasis to bone.
    Singh AS; Figg WD
    J Urol; 2005 Sep; 174(3):820-6. PubMed ID: 16093963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of therapeutic agents to bone to treat metastatic cancer.
    Bagi CM
    Adv Drug Deliv Rev; 2005 May; 57(7):995-1010. PubMed ID: 15876400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
    Iljin K; Ketola K; Vainio P; Halonen P; Kohonen P; Fey V; Grafström RC; Perälä M; Kallioniemi O
    Clin Cancer Res; 2009 Oct; 15(19):6070-8. PubMed ID: 19789329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the stromal microenvironment in prostate cancer.
    Condon MS
    Semin Cancer Biol; 2005 Apr; 15(2):132-7. PubMed ID: 15652458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
    Russell MR; Jamieson WL; Dolloff NG; Fatatis A
    Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone and prostate cancer cell interactions in metastatic prostate cancer.
    Vela I; Gregory L; Gardiner EM; Clements JA; Nicol DL
    BJU Int; 2007 Apr; 99(4):735-42. PubMed ID: 17166237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone-directed treatments for prostate cancer.
    Saad F
    Hematol Oncol Clin North Am; 2006 Aug; 20(4):947-63. PubMed ID: 16861125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When prostate cancer meets bone: control by wnts.
    Emami KH; Corey E
    Cancer Lett; 2007 Aug; 253(2):170-9. PubMed ID: 17462819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-modified bone marrow cell therapy for prostate cancer.
    Wang H; Thompson TC
    Gene Ther; 2008 May; 15(10):787-96. PubMed ID: 18385769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.